Moperone

Moperone (Luvatren, since discontinued) is a typical antipsychotic of the butyrophenone class[1] which is marketed in Japan for the treatment of schizophrenia. It is an antagonist for the D2 (Ki 0.7–1.9 nM), D3 (Ki 0.1–1 nM), and 5-HT2A (Ki 52 nM) receptors. It also has a high binding affinity for the sigma receptors.[2][3]

Moperone
Clinical data
Trade namesLuvatren (discontinued)
ATC code
Identifiers
IUPAC name
  • 1-(4-Fluorophenyl)-4-[4-hydroxy-4-(4-methylphenyl)-1-piperidinyl]-1-butanone
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard100.012.625
Chemical and physical data
FormulaC22H26FNO2
Molar mass355.453 g·mol−1
3D model (JSmol)
SMILES
  • CC1=CC=C(C=C1)C1(O)CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1
InChI
  • InChI=1S/C22H26FNO2/c1-17-4-8-19(9-5-17)22(26)12-15-24(16-13-22)14-2-3-21(25)18-6-10-20(23)11-7-18/h4-11,26H,2-3,12-16H2,1H3
  • Key:AGAHNABIDCTLHW-UHFFFAOYSA-N

References
  1. Gross, H; Kaltenbäck, E (1969). "The clinical position of moperone among the butyrophenones". Nordisk Psykiatrisk Tidsskrift. Nordic Journal of Psychiatry. 23 (1): 4–9. doi:10.3109/08039486909132154. PMID 5354545.
  2. Miyamoto S (2010). "Moperone". In Stolerman IP (ed.). Encyclopedia of Psychopharmacology. Berlin, Heidelberg: Springer. p. 798. doi:10.1007/978-3-540-68706-1_1838. ISBN 978-3-540-68706-1. Retrieved 21 March 2022.
  3. Roth BL, Driscol J. "PDSP Ki Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 21 March 2022.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.